Navigation Links
Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
Date:4/30/2010

uivalents of this patent as well as related patent applications are still pending and if granted would provide further market protection for RG2417.

About Bipolar Disorder

Bipolar disorder, also known as manic depression, is an illness marked by extreme changes in mood, thought, energy and behavior in which a person's mood can alternate between the "poles" of mania and depression.  Bipolar disorder affects more than two million adults in the United States and is usually diagnosed in late adolescence or early adulthood.  Bipolar disorder is a chronic illness associated with substantial morbidity and mortality, ranking worldwide behind only unipolar depression and alcohol abuse among psychiatric illnesses for related disabilities and overall economic burden of illness.  The lifetime financial burden of bipolar disorder in the United States is about $600,000 per patient, depending on resistance to treatment and persistence of symptoms.  Although several therapies are approved for the treatment of bipolar disorder, many individuals are unable to tolerate treatment-related side effects, and incomplete clinical response, relapse and recurrence remain common clinical problems.

About McLean Hospital

McLean Hospital maintains the largest research program of any private, U.S. psychiatric hospital.  It is the largest psychiatric facility of Harvard Medical School, an affiliate of Massachusetts General Hospital and a member of Partners HealthCare.  For additional information, please visit

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
2. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
3. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
6. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
7. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
8. Capstone Reports Additional High Grade Copper-Gold Results From Minto East
9. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
10. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
11. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... und LONDON , July ... , Ziel der Zusammenarbeit sind Entwicklung und Kommerzialisierung ... Plasmaproben zur Steuerung von Therapien mit IRESSA bei ... Neuer Bluttest basiert auf QIAGENs von der ... Rotor-Gene Q, einer Automationsplattform der QIAsymphony-Produktfamilie, laufen  ...
(Date:7/28/2014)... , Germany and ... , Collaboration aims to create and ... to guide the use of IRESSA  for non-small cell ... build on QIAGEN,s FDA-approved  therascreen   EGFR test and is ... of automated instruments  Project enabled by AstraZeneca ...
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma ... it will report its second quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
... Receiving the herpes zoster vaccine was associated with a ... Kaiser Permanente study of 300,000 people that appears in the ... Association . This retrospective study observed the outcomes ... large, diverse population of men and women ages 60 years ...
... 11, 2011 Celleration, Inc., a privately held medical ... products, today announced the closing of an $8 million ... Company,s existing institutional investors participated in this round in ... a new investor. "The addition of ...
Cached Medicine Technology:Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 2Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 3Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 4
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are now ... younger appearance. The Cherry News company has published its ... women explore the availabilities from U.S. retailers at ... the posted guide on the Cherry News website provide ... to some natural ingredient formulas is the high sticker ...
(Date:7/27/2014)... CA (PRWEB) July 27, 2014 Ticket Down ... Tickets at The Forum in Inglewood, California on November 15th. ... and diehard fans can expect to hear songs from this amazing ... of Summer concert in Inglewood, California at The Forum will be ... starting at 10:00 a.m. today local time TicketDown.com. This popular ...
(Date:7/27/2014)... 2014 The constant expansion of companies ... demand for enterprise video. Additional factors that have increased ... areas such as corporate communication, learning and development, security ... all these factors the enterprise video market value has ... reach $35.57 billion in 2018 with a compound annual ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market by ... (OE & Aftermarket), Filter Type (Oil & Fuel), Fuel ... & Forecast to 2018”, defines and segments the global ... forecasting of the global volume and revenue. The market ... revenue of $6.1 billion in 2018, while fuel filter ...
(Date:7/27/2014)... European Bromine market report defines and segments the Bromine market ... market in European region comprises of four major countries. They ... forms a dominant share of Bromine market influences the demand ... through the TOC of the Europe Bromine Market report, to ... the TOC of the Europe Bromine Market report. The report ...
Breaking Medicine News(10 mins):Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4
... muscle, bone behind severity of damage, longer recovery, study finds ... muscles of the lower body appear to be more vulnerable ... new study suggests. , The study analyzed the weight and ... over a three-year period. Sprains, such as to the ankle ...
... ranked among the top competitors in the world for Biathlon competitions. As ... Games to be held in Vancouver, Canada. Lanny and Tracy are crediting ... helping them get the most out of their training. , ... Parsippany, ...
... from Sticky Jewelry make a difference. Sticky J attends the "Walk ... and the Juvenile Diabetes Research Foundation made the day a success. ... ... 2000 Sticky Jewelry (StickyJ.com) has specialized in selling personalized jewelry ...
... of swine flu casesBELIZE CITY, Belize, May 1 ... residents and travelers against the swine flu, which is now ... additional proactive steps towards protection against the pandemic. ... Zone and casinos in the town of Corozal, which borders ...
... SCARBOROUGH, Maine , May 1, Binax, ... diagnostic tests to identify the causative pathogens of infectious ... information has been distributed to customers and potential customers of ... of the BinaxNow(R) Influenza A & B test has not ...
... with cancer that is resistant to standard therapy is the ... obtained in some settings, in many cases the therapies have ... has now been uncovered by a team of researchers, led ... London School of Medicine and Dentistry, London. , In the ...
Cached Medicine News:Health News:Obese Children More Likely to Suffer Lower Body Injuries 2Health News:Twin Sisters Set Their Sights On Biathlon Gold At The 2010 Winter Games 2Health News:Sticky Jewelry & JDRF Team Up to Find a Cure 2Health News:Sticky Jewelry & JDRF Team Up to Find a Cure 3Health News:Belize Takes Further Action Regarding Influenza A (H1N1) to Ensure Safety of Travelers 2
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Anatomical implants for the entire hand, in five sizes...
... a brief magnetic pulse to stimulate deep ... in Magnetic Nerve Stimulators. Based upon equipment ... in 1985. A powerful monophasic stimulator for ... best stimulator for Central Motor Conduction Studies, ...
Medicine Products: